ReviewFrontiers in oncology2026
Unmasking biomarkers in small cell lung cancer: implication for precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) ranks among the most aggressive cancers, posing significant challenges in early diagnosis and treatment with limited therapeutic options. Smoking is one of the major risk factors, which constitutes a substantial proportion of lung cancer cases globally. Despite extensive studies, little progress has been made in treating SCLC, and therefore a striking need for novel therapeutic strategies. Increased genetic and transcriptional heterogeneity has significantly complicated SCLC, including mutations in key regulators such as TP53, RB1, and MYC family genes. Genetic and Transcriptional heterogeneity of SCLC is further exacerbated by the expression of key regulators, including ASCL1, NEUROD1, YAP1, POU2F3, and ATOH1. Because of their unique biological properties, each distinct subtype exhibits a potential specific therapeutic targeting. Biomarkers act as therapeutic guidance in SCLC as they play an important role in early detection, diagnosis, and prognosis. Distinct functional biomarkers, such as genetic, circulating, biochemical, and imaging, provide valuable insights into tumor biology and patient management. Cancer stem cells (CSCs) are an emerging critical challenge in SCLC as they contribute to disease resistance and render the conventional therapies ineffective, leading to tumor recurrence, e.g., CD133, SOX2, and CD44, etc. This in-depth review provides insight into the current understanding of SCLC biology, encompassing its epidemiology, risk factors, genetic features, and molecular subtypes. It also focuses on recent therapeutic insights underlying the promising biomarkers and inhibitors targeting CSCs to overcome drug resistance and improve overall treatment outcomes in SCLC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.